These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 34926138)

  • 21. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
    Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
    J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M
    Law WY; Asaruddin MR; Bhawani SA; Mohamad S
    BMC Res Notes; 2020 Nov; 13(1):527. PubMed ID: 33176880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of bioactive molecule from
    Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Yañez O; Osorio MI; Uriarte E; Areche C; Tiznado W; Pérez-Donoso JM; García-Beltrán O; González-Nilo F
    Front Chem; 2020; 8():595097. PubMed ID: 33614592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
    Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
    In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives.
    Shellenberger BM; Basile ON; Cassel J; Olsen MR; Salvino JM; Montaner LJ; Tietjen I; Henry GE
    Bioorg Med Chem Lett; 2024 Apr; 102():129679. PubMed ID: 38423371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2.
    Chidambaram SK; Ali D; Alarifi S; Radhakrishnan S; Akbar I
    J Infect Public Health; 2020 Nov; 13(11):1671-1677. PubMed ID: 33008777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach.
    Ahmad S; Waheed Y; Ismail S; Najmi MH; Ansari JK
    J Mol Liq; 2021 May; 330():115636. PubMed ID: 33612899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening of phytochemical compounds of
    Krupanidhi S; Abraham Peele K; Venkateswarulu TC; Ayyagari VS; Nazneen Bobby M; John Babu D; Venkata Narayana A; Aishwarya G
    J Biomol Struct Dyn; 2021 Sep; 39(15):5799-5803. PubMed ID: 32627715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CL
    Mathpal S; Joshi T; Sharma P; Pande V; Chandra S
    Struct Chem; 2022; 33(5):1815-1831. PubMed ID: 35153452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis.
    Verma S; Pandey AK
    3 Biotech; 2021 Feb; 11(2):67. PubMed ID: 33457176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
    Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
    J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
    Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
    Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silybin B and Cianidanol Inhibit M
    Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
    Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.